Simultaneous Detection of Hepatitis C Virus (HCV) Core Antigen and Anti-HCV Antibodies Improves the Early Detection of HCV Infection
Open Access
- 1 August 2005
- journal article
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 43 (8) , 3877-3883
- https://doi.org/10.1128/jcm.43.8.3877-3883.2005
Abstract
To evaluate whether a new enzyme immunoassay developed for the simultaneous detection of hepatitis C virus (HCV) core antigen (Ag) and anti-HCV antibodies (anti-HCV Ab) (Monolisa HCV Ag/Ab ULTRA; Bio-Rad) could improve the early detection of HCV infection, we compared its sensitivity to that of anti-HCV, HCV core Ag, and HCV RNA assays. The populations studied included 12 blood donor samples positive for HCV RNA and HCV core Ag but negative for anti-HCV antibodies and 23 hemodialysis patients who developed anti-HCV Ab (seroconversion) during the follow-up. From these 23 individuals, 83 samples sequentially collected prior to seroconversion and 108 samples collected after seroconversion were tested. Six of 12 blood donations were positive by the HCV Ag/Ab assay. In the hemodialysis cohort, the 24 HCV RNA-negative samples were negative by the HCV Ag/Ab assay and 23 of the 59 HCV RNA-positive samples (39%) were positive. The HCV Ag/Ab assay detected HCV infection on average 21.6 days before the most sensitive antibody assay. The HCV Ag/Ab assay did not detect HCV infection as early as the HCV RNA assay (mean delay, 30.3 days) or HCV Ag assay (mean delays, 27.9, and 16.3 days by the HCV core Ag quantification assay and the HCV Ag blood screening assay, respectively). This new assay provides a notable improvement for the early detection of HCV infection during the so-called window period compared with anti-HCV Ab assays and could be a useful alternative to HCV RNA detection or HCV core Ag assays for diagnosis or blood screening when nucleic acid technologies or HCV core Ag detection are not implemented.Keywords
This publication has 47 references indexed in Scilit:
- Evaluation of the Core Antigen Assay as a Second-Line Supplemental Test for Diagnosis of Active Hepatitis C Virus InfectionJournal of Clinical Microbiology, 2004
- Prolonged hepatitis C virus seroconversion in a blood donor, detected by HCV Antigen test in parallel with HCV RNAVox Sanguinis, 2004
- Nucleic acid testing in blood donations reactive to hepatitis C virus antibody, but with an extremely low viral loadVox Sanguinis, 2004
- Hepatitis C Virus (HCV) Core Antigen Assay To Detect Ongoing HCV Infection in Thai Injection Drug UsersJournal of Clinical Microbiology, 2004
- Hepatitis C virus Core Antigen as a predictor of non-response in genotype 1 chronic hepatitis C patients treated with peginterferon α-2b plus ribavirinJournal of Hepatology, 2004
- Combination HCV core antigen and antibody assay on a fully automated chemiluminescence analyzerTransfusion, 2003
- Application de la biologie moléculaire à la sécurité virale transfusionnelle : le dépistage génomique viralTransfusion Clinique et Biologique, 2003
- Use and interpretation of virological tests for hepatitis CHepatology, 2002
- Trends in residual risk of transfusion‐transmitted viral infections in France between 1992 and 2000Transfusion, 2002
- Eradication of Hepatitis C Virus 1b by Interferon in a Health Care Worker with Acute Hepatitis following Needlestick Transmission from a Patient with Chronic Hepatitis C Unresponsive to InterferonScandinavian Journal of Gastroenterology, 2000